Azacitidine Plus Gemtuzumab Ozogamicin (GO): A Novel Combination in the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS) in the Elderly
| Autor: | Patrick J. Stiff, Sucha Nand, John E. Godwin, Eliza Germano, Kevin Barton, Scott E. Smith |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Oncology
Chemotherapy medicine.medical_specialty Gemtuzumab ozogamicin business.industry medicine.medical_treatment Myelodysplastic syndromes Immunology Azacitidine Myeloid leukemia Cell Biology Hematology Leukapheresis medicine.disease Biochemistry Chemotherapy regimen medicine.anatomical_structure hemic and lymphatic diseases Internal medicine White blood cell medicine business medicine.drug |
| Zdroj: | Blood. 108:1981-1981 |
| ISSN: | 1528-0020 0006-4971 |
| Popis: | AML and high-risk MDS in the elderly carry a poor prognosis. Only 46% of AML patients receiving standard chemotherapy achieve complete remission (CR) and treatment-related mortality approaches 30% above age 60. In 2005, we initiated a Phase II trial for elderly patients with newly diagnosed AML or MDS, using the following outpatient treatment schema: If white blood cell (WBC) count at presentation was >10,000/ul, pt was started on hydroxyurea 1500 mg twice daily by mouth. Leukapheresis was performed if WBC >100,000/ul. Once WBC count was |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|